SCL Healthcare Secures U.S. Patent for Genetic Test Predicting Metabolic Syndrome Risk
SCL Healthcare has successfully secured a U.S. patent for a novel genetic testing technology designed to predict an individual’s risk of elevated...
Search results for "U.S."
FDA Grants Streamlined Path for MediPost’s Cartistem, Slashing U.S. Trial Burden
The U.S. Food and Drug Administration has agreed to a significantly streamlined clinical path for Cartistem, a landmark knee osteoarthritis treatment...
More Meat, More Milk, More Illness: The Flawed Science of the New U.S. Dietary Guidelines
In last week’s 128th column, titled “Telling people to eat more protein while cutting saturated fat. ” (Kormedi.
DR Congo’s Historic World Cup Return in Jeopardy Over U.S. Ebola Quarantine Mandate
The Democratic Republic of the Congo’s first World Cup appearance in over half a century is facing a sudden crisis. U. S.
Daewoong Pharmaceutical Acquires U.S. Cellular Reprogramming Tech to Fast-Track Anti-Aging Therapeutics
Daewoong Pharmaceutical is accelerating its research and development into anti-aging therapeutics.
Prioritizing Industry Profits Over Public Health: The Contradictions of the New U.S. Dietary Guidelines
The Dietary Guidelines for Americans have been published every five years since 1980, and to date, 10 editions have...
A Milestone for K-Bio: Celltrion’s Truxima Surpasses Global Blockbuster Rituxan in U.S. Prescriptions
Truxima , a blood cancer treatment developed by Celltrion, has become the first Korean-made biosimilar to rank number...
Why Did the American Heart Association Issue Nutrition Guidelines at Odds with the U.S. Government?
“To improve cardiovascular health, increase your intake of plant-based protein and replace animal saturated fat with...
YuhanUSA and Huinno Partner to Launch AI-Powered ECG Monitoring in the U.S.
YuhanUSA, the U.S. subsidiary of Yuhan Corporation, announced on the 30th that it has signed a strategic business...
Sam Chun Dang Pharm Secures Exclusive U.S. Licensing Deal for Oral Obesity and Diabetes Treatment
Sam Chun Dang Pharm has entered into a significant license-out agreement with an undisclosed U. S.